First-line TQB2450 plus anlotinib combined with paclitaxel and cisplatin for advanced esophageal squamous cell carcinoma (ESCC): Update results of a multi-center phase II trial.

被引：0
|
作者：
Wang, Junsheng
Li, Ning
Guo, Yanzhen
Cheng, Yufeng
Li, Baosheng
Luo, Suxia
机构：
[1] Anyang Canc Hosp, Dept Med Oncol, Anyang, Peoples R China
[2] Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Med Oncol, Zhengzhou, Peoples R China
[3] Henan Univ Sci & Technol, Affiliated Hosp 1, Luoyang, Peoples R China
[4] Qilu Hosp Shandong Univ, Jinan, Peoples R China
[5] Shandong Canc Hosp & Inst, Jinan, Peoples R China
[6] Henan Canc Hosp, Zhengzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16011
引用
收藏
页数：1
相关论文
共 50 条
  • [41] PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis
    Zhao, Jia
    Zhang, Simeng
    Guo, Xiaoyu
    Li, Ce
    Yang, Bowen
    Qu, Xiujuan
    Wang, Shuo
    BMC CANCER, 2023, 23 (01)
  • [42] PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis
    Jia Zhao
    Simeng Zhang
    Xiaoyu Guo
    Ce li
    Bowen Yang
    Xiujuan Qu
    Shuo Wang
    BMC Cancer, 23
  • [43] Cost-Effectiveness Analysis of Toripalimab Plus Paclitaxel and Cisplatin as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma
    Fang, Rui
    Wang, Suiqiong
    Liu, Yongqian
    Xu, Jun
    ADVANCES IN THERAPY, 2023, 40 (03) : 1019 - 1030
  • [44] The efficacy and toxicities of combined lobaplatin with paclitaxel as a first-line chemotherapy for advanced esophageal squamous cell carcinoma
    Chen, Ming-Qiu
    Chen, Cheng
    Lu, Hai-Jie
    Xu, Ben-Hua
    JOURNAL OF THORACIC DISEASE, 2015, 7 (10) : 1749 - 1755
  • [45] Cost-Effectiveness Analysis of Toripalimab Plus Paclitaxel and Cisplatin as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma
    Rui Fang
    Suiqiong Wang
    Yongqian Liu
    Jun Xu
    Advances in Therapy, 2023, 40 : 1019 - 1030
  • [46] Neoadjuvant anlotinib combined with penpulimab for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Updated data from a prospective, phase II trial
    Chen, Yueyun
    Yuan, Yong
    Yang, Yu-Shang
    Lin, Zhen
    Tian, Jiangfang
    Liu, Ting
    Yue, Zheng
    Shi, Hua-Shan
    Hu, Yang
    Ding, Zhen-Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma
    Lee, Jeeyun
    Im, Young-Hyuck
    Cho, Eun Yoon
    Hong, Yong Sang
    Lee, Hyo Rak
    Kim, Hyo Song
    Kim, Mi-Jin
    Kim, Kwhanmien
    Kang, Won Ki
    Park, Keunchil
    Shim, Young Mog
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (01) : 77 - 84
  • [48] A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma
    Jeeyun Lee
    Young-Hyuck Im
    Eun Yoon Cho
    Yong Sang Hong
    Hyo Rak Lee
    Hyo Song Kim
    Mi-Jin Kim
    Kwhanmien Kim
    Won Ki Kang
    Keunchil Park
    Young Mog Shim
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 77 - 84
  • [49] Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma
    Zhang, Bo
    Qi, Ling
    Wang, Xi
    Xu, Jianping
    Liu, Yun
    Mu, Lan
    Wang, Xingyuan
    Bai, Lidan
    Huang, Jing
    CANCER COMMUNICATIONS, 2020, 40 (12) : 711 - 720
  • [50] Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 plus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Survival results of a phase II trial.
    Wang, Yi
    Liu, Hong
    Wang, Qingwei
    Qiao, Naian
    Wang, Jianbo
    Tan, Bingxu
    Cheng, Bo
    Chu, Yunxia
    Zhao, Changhong
    Chen, Xiaoyu
    Cheng, Yufeng
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 411 - 411
12345